These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

712 related articles for article (PubMed ID: 25045276)

  • 1. Molecular pathways in non-alcoholic fatty liver disease.
    Berlanga A; Guiu-Jurado E; Porras JA; Auguet T
    Clin Exp Gastroenterol; 2014; 7():221-39. PubMed ID: 25045276
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Non-Alcoholic Fatty Liver Disease.
    Engin A
    Adv Exp Med Biol; 2017; 960():443-467. PubMed ID: 28585211
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Role of metabolic lipases and lipotoxicity in the development of non-alcoholic steatosis and non-alcoholic steatohepatitis].
    Berlanga A; Guiu-Jurado E; Porras JA; Aragonès G; Auguet T
    Clin Investig Arterioscler; 2016; 28(1):47-61. PubMed ID: 26049666
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Non-alcoholic fatty liver disease.
    Smith BW; Adams LA
    Crit Rev Clin Lab Sci; 2011; 48(3):97-113. PubMed ID: 21875310
    [TBL] [Abstract][Full Text] [Related]  

  • 5. From Non-Alcoholic Fatty Liver to Hepatocellular Carcinoma: A Story of (Mal)Adapted Mitochondria.
    Amorim R; Magalhães CC; Borges F; Oliveira PJ; Teixeira J
    Biology (Basel); 2023 Apr; 12(4):. PubMed ID: 37106795
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fatty Acids and Effects on In Vitro and In Vivo Models of Liver Steatosis.
    Vergani L
    Curr Med Chem; 2019; 26(19):3439-3456. PubMed ID: 28521680
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hepatic Mediators of Lipid Metabolism and Ketogenesis: Focus on Fatty Liver and Diabetes.
    Fernandes GW; Bocco BMLC
    Curr Diabetes Rev; 2021; 17(7):e110320187539. PubMed ID: 33143628
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Role of Lipid and Lipoprotein Metabolism in Non-Alcoholic Fatty Liver Disease.
    Perla FM; Prelati M; Lavorato M; Visicchio D; Anania C
    Children (Basel); 2017 Jun; 4(6):. PubMed ID: 28587303
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Herbal Medicine in the Treatment of Non-Alcoholic Fatty Liver Diseases-Efficacy, Action Mechanism, and Clinical Application.
    Xu Y; Guo W; Zhang C; Chen F; Tan HY; Li S; Wang N; Feng Y
    Front Pharmacol; 2020; 11():601. PubMed ID: 32477116
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fructose as a key player in the development of fatty liver disease.
    Basaranoglu M; Basaranoglu G; Sabuncu T; Sentürk H
    World J Gastroenterol; 2013 Feb; 19(8):1166-72. PubMed ID: 23482247
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of MAP4K4 signaling initiates metabolic reprogramming to protect hepatocytes from lipotoxic damage.
    Anand SK; Caputo M; Xia Y; Andersson E; Cansby E; Kumari S; Henricsson M; Porosk R; Keuenhof KS; Höög JL; Nair S; Marschall HU; Blüher M; Mahlapuu M
    J Lipid Res; 2022 Jul; 63(7):100238. PubMed ID: 35679904
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epigenetics in non-alcoholic fatty liver disease.
    Lee J; Kim Y; Friso S; Choi SW
    Mol Aspects Med; 2017 Apr; 54():78-88. PubMed ID: 27889327
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nonalcoholic fatty liver disease: molecular mechanisms for the hepatic steatosis.
    Koo SH
    Clin Mol Hepatol; 2013 Sep; 19(3):210-5. PubMed ID: 24133660
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Non-alcoholic fatty liver disease and type 2 diabetes mellitus: the liver disease of our age?
    Firneisz G
    World J Gastroenterol; 2014 Jul; 20(27):9072-89. PubMed ID: 25083080
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Nutraceutic Silybin Counteracts Excess Lipid Accumulation and Ongoing Oxidative Stress in an
    Vecchione G; Grasselli E; Cioffi F; Baldini F; Oliveira PJ; Sardão VA; Cortese K; Lanni A; Voci A; Portincasa P; Vergani L
    Front Nutr; 2017; 4():42. PubMed ID: 28971098
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Progression of non-alcoholic steatosis to steatohepatitis and fibrosis parallels cumulative accumulation of danger signals that promote inflammation and liver tumors in a high fat-cholesterol-sugar diet model in mice.
    Ganz M; Bukong TN; Csak T; Saha B; Park JK; Ambade A; Kodys K; Szabo G
    J Transl Med; 2015 Jun; 13():193. PubMed ID: 26077675
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mechanisms of hepatic triglyceride accumulation in non-alcoholic fatty liver disease.
    Kawano Y; Cohen DE
    J Gastroenterol; 2013 Apr; 48(4):434-41. PubMed ID: 23397118
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of fibroblast growth factor 21 in the pathogenesis of non-alcoholic fatty liver disease and implications for therapy.
    Liu J; Xu Y; Hu Y; Wang G
    Metabolism; 2015 Mar; 64(3):380-90. PubMed ID: 25516477
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Redox homeostasis and epigenetics in non-alcoholic fatty liver disease (NAFLD).
    Podrini C; Borghesan M; Greco A; Pazienza V; Mazzoccoli G; Vinciguerra M
    Curr Pharm Des; 2013; 19(15):2737-46. PubMed ID: 23092327
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nonalcoholic fatty liver disease, metabolic risk factors, and hepatocellular carcinoma: an open question.
    Streba LA; Vere CC; Rogoveanu I; Streba CT
    World J Gastroenterol; 2015 Apr; 21(14):4103-10. PubMed ID: 25892859
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 36.